Vitreomacular Interface after Anti–Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration

Influence of the Vitreoretinal Interface on the Treatment with Anti-VEGF for Exudative Age-Related Macular Degeneration

“…Our results show a low incidence of PVD induced by intravitreal injections, as previously described by a large-scale report including 396 eyes (5.6% rate) [21]. It is still unclear whether the injection procedure can influence the occurrence of PVD by some pharmacological or mechanical effect.…”

“…This is probably related to inherent limitations of the SD-OCT (Spectralis®), with a scan depth limited to 1.9 mm, which may fail to image the border of the posterior hyaloid in the vitreous cavity in some cases of PVD, thus leading to a misdiagnosis of completely attached vitreous. This is an important source of bias in studies in which the methodology for grading only included OCT [2, 6, 8, 9, 19-21]. Also, unlike other studies which relied on the presence of VMA, the scope of our paper was broader, as it differentiated groups based on the presence or absence of foveal PVD (either grades 3 or 4 PVD classified by OCT, or grade 4 PVD classified by ultrasonography).…”

Visual Acuity Outcomes of Ranibizumab Treatment in Pathologic Myopic Eyes With Macular Retinoschisis and Choroidal Neovascularization

“…18,24 The injection procedure may induce posterior vitreous detachment in patients with CNV although this is very rare unless there is focal vitreomacular adhesion. 24 Another influencing mechanism might be the shrinkage of the fibrovascular tissue induced by anti-VEGF agents. This contraction might lead to tractional forces and enhance to some degree the separation of the neural retina, which could lead to the onset of MRS.…”

A retrospective study of the influence of the vitreomacular interface on macular oedema secondary to retinal vein occlusion

“…Panretinal laser argon photocoagulation therapy has been shown to induce a total PVD over time 19. There is conflicting evidence on whether anti-VEGF injections induces changes in VRI status; a prospective observational study by Geck et al 20 including 61 eyes with a variety of retinal diseases showed development of a PVD in 15 out of 61 eyes (24.5%) while a cohort study by Veloso et al 21 investigating the development of a PVD in 396 eyes with age-related macular degeneration treated with anti-VEGF showed development of a PVD rarely (5.6% of eyes after an average of 8.3 injections).…”